Innovation Quarter has recognized BMI OrganBank as one of nine life science companies in the iQ to watch in 2026, highlighting the continued growth of Winston-Salem’s regenerative medicine and biotechnology ecosystem.
The annual feature spotlights companies advancing science, technology, and translational innovation across the Innovation Quarter. This year’s list reflects the expanding depth of the region’s life science cluster and the momentum of organizations addressing real-world clinical and system-level challenges.
Why BMI OrganBank Was Selected
BMI OrganBank is developing organ preservation technologies designed to support improved evaluation, preservation, and transportation of donor organs—beginning with kidneys. By addressing key limitations in how donated organs are preserved and assessed, the company aims to support broader utilization of available organs and strengthen transplant readiness across the system.
In the article, Innovation Quarter notes BMI OrganBank’s recent progress, including growth of the team, investment from the National Kidney Foundation Innovation Fund, support from the Regenerative Medicine Engine, and the receipt of FDA Breakthrough Device Designation for its kidney preservation technology.
